ConductScience.org, home

Paper29856472

Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.

Chen M and 11 others. Aliment Pharmacol Ther, 2018. Cited by 51 papers, by iCite.

Cite this record

ConductScience Library. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Papers, record 29856472. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29856472

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
PubMed
Journal
Aliment Pharmacol Ther
PubMed
Year
2018
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
51
iCite
Relative citation ratio, by iCite
2.5
iCite
Revised in PubMed
2019-08-19
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen MM
2Tang TCT-C
3Wang YY
4Shui JJ
5Xiao XHX-H
6Lan XX
7Yu PP
8Zhang CC
9Wang SHS-H
10Yao JJ
11Zheng HHhttps://orcid.org/0000-0002-0494-1217
12Huang DQD-Q

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DiarrheaMajor topic
Drugs, Chinese HerbalMajor topic
Irritable Bowel SyndromeMajor topic
Abdominal Pain
Administration, Oral
Adult
Dosage Forms
Double-Blind Method
Female
Humans
Male
Middle Aged
Placebos
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02538692Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel SyndromeDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in30588695Editorial: Tong-Xie-Yao-Fang (TXYF) for irritable bowel syndrome with diarrhoea (IBS-D)-ancient medicine meets modern study.https://conductscience.org/library/papers/30588695PubMed
Comment in30588696Editorial: Tong-Xie-Yao-Fang (TXYF) for irritable bowel syndrome with diarrhoea (IBS-D)-ancient medicine meets modern study. Authors' reply.https://conductscience.org/library/papers/30588696PubMed

Download CSV of comments and corrections

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.

PMIDTitleJournalYearIn PapersSource
42979303Xifenghuashi formula ameliorates diarrhea predominant-irritable bowel syndrome by modulating the gut microbiota and the bile acid-FXR-FGF axis: A human trial and an animal experiment.J Tradit Complement Med2026https://conductscience.org/library/papers/42979303PubMed
42572206Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome.Phytother Res2026https://conductscience.org/library/papers/42572206PubMed
41641200Clinical efficacy of Xifeng Huashi and its effect on mental status in patients with diarrheal irritable bowel.World J Psychiatry2026https://conductscience.org/library/papers/41641200PubMed
41599795Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines.Nutrients2026https://conductscience.org/library/papers/41599795PubMed
41096612Natural Remedies for Irritable Bowel Syndrome: A Comprehensive Review of Herbal-Based Therapies.Int J Mol Sci2025https://conductscience.org/library/papers/41096612PubMed
41034986Changji'an formula alleviates visceral hypersensitivity of a post-inflammatory IBS-D mouse model via NGF/TrkA signaling pathway.BMC Complement Med Ther2025https://conductscience.org/library/papers/41034986PubMed
39998756Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis.Qual Life Res2025https://conductscience.org/library/papers/39998756PubMed
39870499Chinese herbal formula Tongxie Yaofang granules for diarrhoea-predominant irritable bowel syndrome: a randomised, double-blind, placebo-controlled, phase II trial.BMJ Open2025https://conductscience.org/library/papers/39870499PubMed
39669195Herbal placebo response in clinical trials on irritable bowel syndrome: a systematic review and meta-analysis.Front Pharmacol2024https://conductscience.org/library/papers/39669195PubMed
39355776Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.Front Pharmacol2024https://conductscience.org/library/papers/39355776PubMed
39143474How fragile the positive results of Chinese herbal medicine randomized controlled trials on irritable bowel syndrome are?BMC Complement Med Ther2024https://conductscience.org/library/papers/39143474PubMed
39081703Tongxieyaofang Decotion Alleviates IBS by Modulating CHRM3 and Gut Barrier.Drug Des Devel Ther2024https://conductscience.org/library/papers/39081703PubMed
38186470Atractylodes macrocephala-Paeonia lactiflora Class Formula for the Treatment of Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis and Trial Sequential Analysis.Cureus2023https://conductscience.org/library/papers/38186470PubMed
37397480Utilization patterns and prescription characteristics of traditional Chinese medicine among patients with irritable bowel syndrome in Taiwan.Front Pharmacol2023https://conductscience.org/library/papers/37397480PubMed
36590561Paeoniflorin alleviates inflammatory response in IBS-D mouse model via downregulation of the NLRP3 inflammasome pathway with involvement of miR-29a.Heliyon2022https://conductscience.org/library/papers/36590561PubMed
36376576Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea.Dig Dis Sci2023https://conductscience.org/library/papers/36376576PubMed
36091782Systematic review and meta-analysis of Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: Evidence for clinical practice and future trials.Front Pharmacol2022https://conductscience.org/library/papers/36091782PubMed
35966738Effect and Mechanism of Flavored Tongxie Yaofang Decoction for Diarrheal Irritable Bowel Syndrome under Intestinal Microecology.Evid Based Complement Alternat Med2022https://conductscience.org/library/papers/35966738PubMed
35645323An Asian perspective on irritable bowel syndrome.Intest Res2023https://conductscience.org/library/papers/35645323PubMed
35635135Herbal Formula Shenling Baizhu San for Chronic Diarrhea in Adults: A Systematic Review and Meta-analysis.Integr Cancer Ther2022https://conductscience.org/library/papers/35635135PubMed

See all 30 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29856472

GET https://conductscience.org/api/papers/v1/29856472/cited_by?page=2